Phase II proof-of-concept study of andexanet alfa with betrixaban in volunteers

Trial Profile

Phase II proof-of-concept study of andexanet alfa with betrixaban in volunteers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Andexanet alfa (Primary)
  • Indications Haemorrhage
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors Portola Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2016 Results of Cohort 1 and 2 (n=18) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 07 Nov 2016 According to a Portola Pharmaceuticals media release, data from the study will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting 2016.
    • 26 Feb 2016 According to a Portola Pharmaceuticals media release, the company plans to present data from this phase 2 proof-of-concept study of andexanet and betrixaban at a medical conference in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top